IP Library Granted Patent US 7,754,190
Granted Patent B2
US 7,754,190 · App. 10/602,077 · Granted Jul 13, 2010

Method for determining drug effects using quantitative EEG

Assignee: CNS Response, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,754,190
App. No.
10/602,077
Granted
Jul 13, 2010
Kind
B2
Abstract

Neurophysiologic information such as quantitative electroencephalography (QEEG) is used in a method for classifying, diagnosing, and treating physiologic brain imbalances. Neurophysiologic information is also used to guide sample selection in clinical tests for psychopharmacologic drug candidates. Finally, neurophysiologic information is used for remotely assessing and treating patients with physiologic brain imbalances.

Claims (24)

1. A method for determining medication efficacy, comprising:

a) providing;

i) a patient having a physiologic brain imbalance, wherein said imbalance is identified using a first electroencephalography recording, and

ii) a medication; and,

b) converting said first electroencephalography recording to at least one first multivariate outcome measurement wherein said first outcome measurement comprises a plurality of first univariate Z scores, wherein said first multivariate outcome measurement is derived from a frequency band selected from the group consisting of delta, theta, alpha, and beta;

c) administering said medication to said patient;

d) obtaining a second electroencephalography recording from said patient and converting said second electroencephalography recording to at least one second multivariable outcome measurement wherein said second outcome measurement comprises a plurality of second univariate Z scores, wherein said second multivariate outcome measurement is derived from a frequency band selected from the group consisting of delta, theta, alpha, and beta; and

e) comparing said first multivariate outcome measurement with said second multivariate outcome measurement wherein a differential change between said first and second measurement determines said medication efficacy.

2. The method according to claim 1 , wherein said comparing further comprises using a reference database.

3. The method according to claim 1 , wherein said difference between said first multivariate outcome measurement and second follow-up multivariate outcome measurement is proportional to the efficacy of said medication.

4. The method of claim 1 , wherein said delta frequency band comprises a first set of univariate measurements selected from the group consisting of absolute power, relative power, coherence, and symmetry.

5. The method of claim 1 , wherein said theta frequency band comprises a second set of univariate measurements selected from the group consisting of absolute power, relative power, coherence, and symmetry.

6. The method of claim 1 , wherein said alpha frequency band comprises a third set of univariate measurements selected from the group consisting of absolute power, relative power, coherence, and symmetry.

7. The method of claim 1 , wherein said beta frequency band comprises a fourth set of univariate measurements selected from the group consisting of absolute power, relative power, coherence, and symmetry.

8. A method for determining medication efficacy, comprising:

a) providing;

i) a patient having a physiologic brain imbalance, wherein said imbalance is identified using a first electroencephalography recording; and

ii) a medication;

b) converting said first electroencephalography recording to at least one first multivariate outcome measurement wherein said first outcome measurement comprises a plurality of first univariate Z scores, wherein said first multivariate outcome measurement is derived from a frequency band selected from the group consisting of ranging from approximately 0.5-3.5 Hertz, ranging from approximately 3.5-7.5 Hertz, ranging from approximately 7.5-12.5 Hertz, and ranging from approximately 12.5-35 Hertz;

c) administering said medication to said patient, thereby resulting in a medicated patient;

d) obtaining a second electroencephalography recording from said medicated patient and converting said second electroencephalography recording to at least one second multivariable outcome measurement wherein said second outcome measurement comprises a plurality of second univariate Z scores, wherein said second multivariate outcome measurement is derived from a frequency band selected from the group consisting of ranging from approximately 0.5-3.5 Hertz, ranging from approximately 3.5-7.5 Hertz, ranging from approximately 7.5-12.5 Hertz, and ranging from approximately 12.5-35 Hertz; and

e) comparing said first multivariate outcome measurement with said second multivariate outcome measurement wherein a differential change between said first and second measurement determines said medication efficacy.

9. The method according to claim 8 , wherein said comparing further comprises using a reference database.

10. The method according to claim 8 , wherein said difference between said first multivariate outcome measurement and second follow-up multivariate outcome measurement is proportional to the efficacy of said medication.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2019
From: MYND ANALYTICS, INC.
To: MYND ANALYTICS, INC., A CALIFORNIA CORPORATION
Reel/Frame 049713/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2018
From: CNS RESPONSE, INC.
To: MYND ANALYTICS, INC.
Reel/Frame 046347/0417 →
CHANGE OF NAME Recorded Feb 26, 2016
From: CNS RESPONSE, INC.
To: MYND ANALYTICS, INC.
Reel/Frame 037940/0531 →
SECURITY INTEREST Recorded May 15, 2015
From: CNS RESPONSE, INC.
To: RSJ PRIVATE EQUITY INVESTICNI FOND S PROMENNYM ZAKLADNIM KAPITALEM A.S. AS REPRESENTATIVE SECURED PARTY
Reel/Frame 035650/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2010
From: SUFFIN, STEPHEN C.; EMORY, W. HAMLIN
To: CNS RESPONSE, INC.
Reel/Frame 025519/0109 →
Continuity (4)
Division 0950114900 · Feb 9, 2000
Continuation In Part 0914859100 · Sep 4, 1998
Provisional Application 6005805200 · Sep 6, 1997
Related Publication 20040059241A1 · Mar 25, 2004